newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 wit